Intelligence, benchmarking, and certification for risk and compliance leaders, from the institution setting the standard since 1922.
The Federal Trade Commission and Food and Drug Administration have signaled they will be increasing their oversight of any potential antitrust behavior in the biologics market, according to a joint statement issued by the U.S. agencies.
Jaclyn Jaeger is a freelance contributor to Compliance Week after working for the company for 15 years. She writes on a wide variety of topics, including ethics and compliance, risk management, legal,... More by Jaclyn Jaeger
We'll send a verification code to %EMAIL%.
